Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial

Bibliographic Details
Title:	Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial
Authors:	Schochter, F.^{Aff1, IDs10549026080692_cor1}, Friedl, T.W.P.^Aff1, Schäffler, H.^Aff1, Meier-Stiegen, F.^{Aff2, Aff3}, Pfister, K.N.^Aff1, Riethdorf, S.^Aff4, Wiesmüller, L.^Aff1, Neubauer, H.^{Aff2, Aff3}, Müller, L.^Aff5, Wimberger, P.^{Aff6, Aff7}, Fasching, P.A.^Aff8, Lorenz, R.^Aff9, Hempel, T.^Aff10, Heublein, S.^Aff1, Hartkopf, A.^Aff11, Pantel, K.^Aff4, Rack, B.^Aff1, Müller, V.^Aff12, Fehm, T.^{Aff2, Aff3}, Janni, W.^Aff1, Cieslik, J.P.^{Aff2, Aff3}
Source:	Breast Cancer Research and Treatment. 219(3)
Database:	Springer Nature Journals

Description
ISSN:	01676806 15737217
DOI:	10.1007/s10549-026-08069-2